524516 BACPHAR

Bacil Pharma Share Price

₹43.00 -0.57 (-1.31%)

23 Feb, 2025 11:11

SIP TrendupStart SIP in BACPHAR

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -0.42%
  • Over 3 Month -1.01%
  • Over 6 Month + 172.84%
  • Over 1 Year + 383.15%
SIP Lightning

Smart Investing Starts Here Start SIP with Bacil Pharma for Steady Growth!

Invest Now

Bacil Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Bacil Pharma Financials

Bacil Pharma Technicals

EMA & SMA

Current Price
₹43.00
-0.57 (-1.31%)
pointer
  • stock-down_img
  • Bearish Moving Average 12
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹44.35
  • 50 Day
  • ₹45.41
  • 100 Day
  • ₹42.89
  • 200 Day
  • ₹35.69

Resistance and Support

43.19 Pivot Speed
  • R3 43.95
  • R2 43.76
  • R1 43.38
  • S1 42.81
  • S2 42.62
  • S3 42.24

What's your outlook on Bacil Pharma?

You can only vote for once

Bacil Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-21 Quarterly Results
2024-10-23 Quarterly Results
2024-10-15 Others
2024-09-27 Increase in Authorised Capital
2024-08-14 Quarterly Results

Bacil Pharma F&O

Bacil Pharma Shareholding Pattern

No data available.

About Bacil Pharma

  • NSE Symbol
  • BACPHAR
  • BSE Symbol
  • 524516
  • ISIN
  • INE711D01018

Similar Stocks to Bacil Pharma

Bacil Pharma FAQs

Bacil Pharma share price is ₹43 As on 23 February, 2025 | 10:57

The Market Cap of Bacil Pharma is ₹25.3 Cr As on 23 February, 2025 | 10:57

The P/E ratio of Bacil Pharma is 72.8 As on 23 February, 2025 | 10:57

The PB ratio of Bacil Pharma is 44 As on 23 February, 2025 | 10:57

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23